🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07804420
Recruiting Not applicable

A Cluster-Randomized Trial of a Hypertension Risk Model-Based Precision Intervention in High-Risk Adults in Shunyi District

NCT07804420 · tracked via the Priya Life Science China tracker
Sponsor
Peking University
Phase
Not applicable
Started
2026-04-01
Last updated
2026-09-16

Condition(s) studied

Hypertension

Investigational drug(s) / intervention(s)

Hypertension Risk Model-Based Precision InterventionStandard Health Education

Hypertension Risk Model-Based Precision Intervention: A multicomponent precision health management intervention based on individual hypertension risk assessment. The intervention combines a WeChat-based hypertension risk assessment and management program with community physician follow-up. Participants receive personalized health education based on individual risk factors; behavioral goal setting and tracking for modifiable risk factors such as weight control, salt intake, and physical activity; health management tools such as salt-restriction spoons and oil-control containers; guidance on regular blood pressure monitoring; and referral to a hypertension specialist when clinically indicated. Follow-up is conducted at 1, 3, and 6 months.

Standard Health Education: Participants receive standard non-personalized hypertension prevention and healthy lifestyle education through written educational materials, general health information, and routine health education sessions conducted once every three months at community health service centers. Participants continue to receive usual community healthcare services and may seek routine medical consultation according to standard community healthcare procedures.

Study summary

This community cluster-randomized controlled trial aims to evaluate the effectiveness of a hypertension risk model-based precision intervention among adults at high risk of developing hypertension in Shunyi District, Beijing, China. Four community clusters are included in the trial and are allocated in a 1:1 ratio to either a precision intervention group or a control group, with two community clusters in each group. Eligible participants are adults aged 35 to 65 years who are identified as having a predicted hypertension risk greater than 20%, have not been diagnosed with hypertension, and are not taking antihypertensive medications. Participants in the intervention clusters receive individualized health management delivered through a WeChat mini-program and community healthcare providers, including personalized health education, behavioral goal setting and follow-up, blood pressure monitoring guidance, and health management tools. Participants in the control clusters receive standard, non-personalized health education and usual community health services. The primary outcomes are changes in systolic and diastolic blood pressure. Secondary outcomes include hypertension-related status, incidence of new-onset hypertension, changes in anthropometric measures, and hypertension-related knowledge and beliefs.

Eligibility

Sex
ALL
Min age
35 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria: Aged 35 to 65 years. Permanent resident of Shunyi District, Beijing, China. Identified as being at high risk of developing hypertension through the Hypertension Risk Assessment WeChat mini-program, with a predicted hypertension risk greater than 20%. No current diagnosis of hypertension, with systolic blood pressure \<140 mmHg and diastolic blood pressure \<90 mmHg, and not currently taking antihypertensive medication. Willing to participate in the study and able to provide written informed consent. Owns a smartphone and is able to use basic WeChat functions. Exclusion Criteria: Previously diagnosed hypertension or current use of antihypertensive medications. History of serious cardiovascular or cerebrovascular disease, such as myocardial infarction or stroke. Severe hepatic or renal dysfunction, malignant tumor, serious psychiatric disorder, or other serious disease. Planning to move out of Shunyi District within the next 9 months. Currently participating in another similar intervention study.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Shunyi District Center for Disease Control and Prevention, Beijing Beijing Beijing Municipality Recruiting

More Peking University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07804420 on ClinicalTrials.gov ↗ ← All trials in China